A revolutionary stem-cell therapy must proceed responsibly to achieve its full potential
By Editors,
Nature
| 08. 18. 2026
It is 20 years since induced pluripotent stem cells shook biomedicine. Public trust must be retained now that clinical trials are well under way.
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of encouragement. Some tell him that they hope his research will lead to cures for family members who are battling severe illnesses. “I feel deeply humbled and grateful,” says Yamanaka, who splits his time between Kyoto University and the Gladstone Institutes in San Francisco, California.
Some of the hoped-for cures could be nearing reality. It has been quite a wait — 20 years, in fact — since the paper1 that shook biomedical research and won Yamanaka a share of the 2012 Nobel Prize in Physiology or Medicine. In it, he and his colleague, Kazutoshi Takahashi, also at Kyoto University, unveiled a way to turn back time in adult mouse cells, erasing their identity and reprogramming them to an embryonic-like state — all by switching on just four genes.
That discovery opened up a possible way to treat disease. If those...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...